Recent FDA actions offer long-awaited clarity on what constitutes a ‘minor change’ to solid oral OTC dosage forms, providing manufacturers with a clearer pathway for certain modifications while ...

DUBLIN--(BUSINESS WIRE)--The "U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, ...

IRVINE, Calif.--(BUSINESS WIRE)--Forma Life Sciences, Inc. today announced its launch as an independent, operator-owned contract development and manufacturing organization (CDMO) focused on oral solid ...

The high-potent oral solid dosage (HP-OSD) contract manufacturing market is projected to grow from USD 6.59 billion in 2025 to USD 15.32 billion by 2035, reflecting a steady value-based CAGR of 8.8%.

Forma Life Sciences Launches U.S. Based Contract Development and Manufacturing Organization (CDMO) for Oral Solid Dosage Development and Commercial Manufacturing in Irvine, California Forma Life ...